You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Mallinckrodt
AstraZeneca
Harvard Business School
Merck

Last Updated: February 22, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Pacritinib


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Pacritinib?

Pacritinib is an investigational drug.

There have been 23 clinical trials for Pacritinib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Primary Myelofibrosis, Leukemia, and Thrombocytosis. The leading clinical trial sponsors are CTI BioPharma, Covance, and Washington University School of Medicine.

There are eleven US patents protecting this investigational drug and one hundred and eight international patents.

Recent Clinical Trials for Pacritinib
TitleSponsorPhase
Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersUniversity of Michigan Cancer CenterPhase 1
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)CTI BioPharmaPhase 2
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)Dutch Cancer SocietyPhase 2

See all Pacritinib clinical trials

Clinical Trial Summary for Pacritinib

Top disease conditions for Pacritinib
Top clinical trial sponsors for Pacritinib

See all Pacritinib clinical trials

US Patents for Pacritinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pacritinib   Start Trial Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   Start Trial
Pacritinib   Start Trial Biomarkers and combination therapies using oncolytic virus and immunomodulation DNATRIX, INC. (Houston, TX) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)   Start Trial
Pacritinib   Start Trial Oxygen linked pyrimidine derivatives S*BIO Pte Ltd. (Singapore, SG)   Start Trial
Pacritinib   Start Trial Oxygen linked pyrimidine derivatives Cell Therapeutics, Inc. (Seattle, WA)   Start Trial
Pacritinib   Start Trial 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt CTI Biopharma Corp. (Seattle, WA)   Start Trial
Pacritinib   Start Trial 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-maleate salt CTI Biopharma Corp. (Seattle, WA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pacritinib

Drugname Country Document Number Estimated Expiration Related US Patent
Pacritinib Australia 2012345732 2031-11-30   Start Trial
Pacritinib Australia 2016244212 2031-11-30   Start Trial
Pacritinib Brazil 112014013224 2031-11-30   Start Trial
Pacritinib Canada 2856722 2031-11-30   Start Trial
Pacritinib China 104185420 2031-11-30   Start Trial
Pacritinib China 107898790 2031-11-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Merck
Harvard Business School
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.